Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehdi Touat

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type GliomaAnna Luisa Di Stefano, Alessandra Fucci, Veronique Frattini, et al.
The Journal of Clinical Investigation|February 16, 2018
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockadeMehdi Touat, Tony Sourisseau, Nicolas Dorvault, et al.
JCO Precision Oncology|June 1, 2023
Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With GliomaPatrick R Benusiglio, Fikret Elder, Mehdi Touat, et al.
Neuro-Oncology|June 24, 2024
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Martin J van den Bent, Pim J French, Daniel Brat, et al.
Neurology|June 5, 2021
Sustained Tumor Control With MAPK Inhibition in <i>BRAF</i> V600-Mutant Adult Glial and Glioneuronal TumorsGiulia Berzero, Luisa Bellu, Capucine Baldini, et al.
The Lancet Regional Health. Europe|February 3, 2025
Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort studyLotta Plomp, Hortense Chassepot, Dimitri Psimaras, et al.
Neuro-Oncology|December 26, 2024
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant gliomaMacarena I de la Fuente, Mehdi Touat, Martin J van den Bent, et al.
Neuro-Oncology|July 31, 2024
A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patientsMary Jane Lim-Fat, Jennifer A Cotter, Mehdi Touat, et al.
The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.
Neuro-Oncology|August 20, 2024
Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumorsHia S Ghosh, Ruchit V Patel, Eleanor Woodward, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type GliomaAnna Luisa Di Stefano, Alessandra Fucci, Veronique Frattini, et al.
The Journal of Clinical Investigation|February 16, 2018
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockadeMehdi Touat, Tony Sourisseau, Nicolas Dorvault, et al.
JCO Precision Oncology|June 1, 2023
Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With GliomaPatrick R Benusiglio, Fikret Elder, Mehdi Touat, et al.
Neuro-Oncology|June 24, 2024
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Martin J van den Bent, Pim J French, Daniel Brat, et al.
Neurology|June 5, 2021
Sustained Tumor Control With MAPK Inhibition in <i>BRAF</i> V600-Mutant Adult Glial and Glioneuronal TumorsGiulia Berzero, Luisa Bellu, Capucine Baldini, et al.
The Lancet Regional Health. Europe|February 3, 2025
Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort studyLotta Plomp, Hortense Chassepot, Dimitri Psimaras, et al.
Neuro-Oncology|December 26, 2024
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant gliomaMacarena I de la Fuente, Mehdi Touat, Martin J van den Bent, et al.
Neuro-Oncology|July 31, 2024
A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patientsMary Jane Lim-Fat, Jennifer A Cotter, Mehdi Touat, et al.
The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.
Neuro-Oncology|August 20, 2024
Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumorsHia S Ghosh, Ruchit V Patel, Eleanor Woodward, et al.
Pageof 10